Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT
Jennifer L. Gommerman, Keith Giza, Stuart Perper, Irene Sizing, Apinya Ngam-ek, Cheryl Nickerson-Nutter, Jeffrey L. Browning
Jennifer L. Gommerman, Keith Giza, Stuart Perper, Irene Sizing, Apinya Ngam-ek, Cheryl Nickerson-Nutter, Jeffrey L. Browning
View: Text | PDF
Article Autoimmunity

A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT

  • Text
  • PDF
Abstract

In studies using genetically deficient mice, a role for the lymphotoxin (LT) system in the pathogenesis of experimental autoimmune encephalomyelitis (EAE) has remained controversial. Here, we have reassessed this conclusion by using a fusion protein decoy that blocks the LT pathway in vivo without evoking the developmental defects inherent in LT-deficient mice. We have found that inhibition of the LT pathway prevented disease in two models of EAE that do not rely on the administration of pertussis toxin. Surprisingly, disease attenuation was due to specific blockade of LTαβ binding rather than the binding of LIGHT to its receptors. In a third system that requires pertussis toxin, LT inhibition did not affect disease, as was observed when the same model was used with LT-deficient mice. Disease prevention in pertussis toxin–free models was associated with defects in T cell responses and migration. When the DO11.10 T cell transgenic system was used, inhibition of the LT pathway was shown to uncouple T cell priming from T cell recall responses. Therefore, it is hypothesized that the LT pathway and its ability to maintain lymphoid microenvironments is critical for sustaining late-phase T cell responses in multiple sclerosis.

Authors

Jennifer L. Gommerman, Keith Giza, Stuart Perper, Irene Sizing, Apinya Ngam-ek, Cheryl Nickerson-Nutter, Jeffrey L. Browning

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Disease is prevented by LTβR-Ig or anti-LTβ treatment in an acute rat EA...
Disease is prevented by LTβR-Ig or anti-LTβ treatment in an acute rat EAE model. (a) Lewis rats were treated with either control human IgG (diamonds), LTβR-Ig (circles), or N297Q LTβR-Ig (squares) 1 day prior to immunization with MBP-peptide in CFA, and disease was scored by measuring tail and limb paralysis. (b) Dose response to LTβR-Ig was evaluated in the rat EAE model by administering LTβR-Ig at the indicated dose. The percentage of inhibition of disease was calculated by determining the decrease in clinical score on the peak day of disease. (c) Lewis rats were treated with either control huIgG (diamonds), HVEM-Ig (squares), anti-murine LTβ (open circles), or control mAb HA4/8 (filled circles) 1 day prior to immunization with MBP-peptide in CFA. Treatment with anti-LTβ and HA4/8 was continued on days 3, 5, and 7 after immunization. Eight animals were used for each group, and the experiment was performed three times with similar results. Experiments using anti-LTβ, HVEM-Ig, and HA4/8 were performed two times with similar results.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts